IKK inhibition by BMS-345541 suppresses breast tumorigenesis and metastases by targeting GD2+ cancer stem cells

Venkata Lokesh Battula1,2, Khoa Nguyen1, Jeff Sun1, Mary Kathryn Pitner2, Bin Yuan1, Chandra Bartholomeusz2, Numsen Hail1 and Michael Andreeff1

1 Department of Leukemia, Section of Molecular Hematology and Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA
2 Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Correspondence to: Venkata Lokesh Battula, email: vbattula@mdanderson.org
Correspondence to: Michael Andreeff, email: mandreef@mdanderson.org

Keywords: breast cancer, cancer stem cells, GD2, GD3 synthase, NFκB

Received: October 13, 2016 Accepted: March 01, 2017 Published: March 16, 2017

ABSTRACT

We have identified that the ganglioside GD2 is a marker for breast cancer stem cells (BCSCs), and that targeting the enzyme GD3 synthase (GD3S, which regulates GD2 biosynthesis) reduces breast tumorigenesis. The pathways regulating GD2 expression, and their anomalous functions in BCSC, are unclear. Proteomic analysis of GD2+ and GD2- cells from breast cancer cell lines revealed the activation of NFκB signaling in GD2+ cells. Dose- and time-dependent suppression of NFκB signaling by the small molecule inhibitor BMS-345541 reduced GD2+ cells by > 90%. Likewise, BMS-345541 inhibited BCSC GD3S expression, mammosphere formation, and cell migration/invasion in vitro. Breast tumor-bearing mice treated with BMS-345541 showed a statistically significant decrease in tumor volume and exhibited prolonged survival compared to control mice, with a median survival of 78 d for the BMS-345541-treated group vs. 58 d for the controls. Moreover, in an experimental metastases model, treatment with BMS-345541 reduced the lung metastases by > 5-fold. These data suggest that GD2 expression and function, and NFκB signaling, are related, and they control BCSCs tumorigenic characteristics. Thus, the suppression of NFκB signaling by BMS-345541 is a potentially important advance in controlling breast cancer growth and metastases.

INTRODUCTION

Breast cancer stem cells (BCSCs) are a subpopulation of primary breast tumor cells that are resistant to most conventional chemotherapeutic agents, and hence they can cause secondary primary tumors if they are not eradicated from the body via surgery or radiotherapy [1, 2]. These cells can also cause tumor metastasis through their ability to dissociate from the primary tumor and invade vicinal tissues and vasculature [3]. Because of their quiescent nature, BCSCs are difficult to target in general [4], and molecular characteristics that are specific for these cells are in desperate need of identification.

Recently, our group identified the ganglioside GD2 as a marker for BCSCs [5]. GD2 is co-expressed on well-established CD44+CD24−CD133+ cells, and GD2+ cells can form mammospheres in low-adherent conditions, migrate, and invade in vitro. They can also initiate tumors from as few as 10 cells in vivo. We also found that GD3 synthase (GD3S), an enzyme that synthesizes GD3 that is a precursor molecule for GD2, was highly expressed on GD2+ breast cancer cells [5]. Genetic and pharmacologic inhibition of GD3S reduced GD2 expression and inhibited tumor growth in vivo. Inhibition of GD3S expression also reduced lung metastases of breast cancer cells in immunodeficient mice [6].

We also recently reported that the overexpression of the NFκB (p65) super-repressor inhibited GD3S expression in breast cancer cells [6]. NFκB is activated via “canonical” and “non-canonical” pathways. The canonical pathway is triggered by pro-inflammatory cytokines such
as TNFα and IL-1. The non-canonical NFκB pathway is activated by TNF family cytokines [7, 8], CD40 ligand [7], B-cell activating factor (BAFF/TNFSF13B) [9], and receptor activator of NFκB ligand (RANKL/TNFSF11) [10] resulting in the activation of RelB/p52 complexes [9]. NFκB is a known regulator of many aberrant cellular functions in cancer cells, including cell migration, chemoresistance, and tumor engraftment [11-13] Yamamoto et al., reported that NFκB non-cell autonomously regulated cancer stem cells in basal-like breast cancer, suggesting a major role of this signaling pathway in BCSC function [14].

To date, the signaling pathways regulating GD2 expression and their anomalous functions in BCSC are unclear. In this manuscript, we show that NFκB signaling is activated in GD2+ BCSCs and that the inhibition of this signaling by the IKKα/β inhibitor BMS-345541 suppresses BCSC tumorigenic functions, including metastasis. In addition, we identify BMS-345541 as a potential therapeutic agent to inhibit the spontaneous generation of GD2+ BCSCs, which could conceivably inhibit breast cancer growth and metastases.

RESULTS

Proteomic profiling revealed activation of NFκB signaling in GD2+ compared to GD2- cells

The signaling pathways regulating GD3S and GD2 expression are unclear. To identify potential components of these pathways, GD2+ and GD2− cells from MDA-MB-231 and SUM159 breast cancer cell lines were sorted using FACS, and the cell lysates were assayed on a Kinexus antibody microarray. A total of 850 different validated proteins, belonging to various signaling pathways, were assayed in each sample. The proteins that were differentially expressed or phosphorylated in the GD2+ and the GD2− SUM159 (Table 1) and MDA-MB-231 cells (supplementary Table 1) were organized based on their z-scores [15]. Pathway analysis of the differentially expressed and phosphorylated proteins using Ingenuity pathway analysis tool revealed the activation of NFκB, STAT3, focal adhesion kinase (FAK), p53, platelet-derived growth factor β (PDGFβ), and p38 MAPK signaling pathways, among others, in the GD2+ cells (Supplementary Figure 1).

To validate the antibody array data, we performed CyTOF. MDA-MB-231 cells were stained with antibodies to identify both extra-cellular and intra-cellular targets. CyTOF identified a fraction (i.e., 13% ± 2%) of GD2+ cells equivalent to that observed (i.e., 14 ± 2.5%) using conventional flow cytometry (Figure 1). The multi-parameter CyTOF data generated from MDA-MB-231 cells were analyzed by SPADE software [16]. Figure 1B shows the tree structures generated by SPADE analysis, revealing that pPI3K and pmTOR were down-regulated in the GD2+ cells. Interestingly, pNFκB was up-regulated in GD2+ cells compared with their GD2− counterparts. Next, to investigate if GD2 and GD3S expression was dependent on NFκB signaling, we knocked down IKKα (a crucial factor in mediating canonical and non-canonical NFκB signaling), in MDA-MB-231 using shRNA (Figure 2C). mRNA and protein expression analysis validated inhibition of IKKα expression by 70 to 90% in IKKα knock-down, compared to control, cells (Figure 2C through 2E). Interestingly, GD3S expression was downregulated ~40% in the IKKα knockdown compared to controls (Figure 2D and 2E). More importantly, flow cytometry analysis revealed >80% decrease in the percentage of GD2+ cells in IKKα− KD cells compared to the control cells (Figure 2F and 2G). These data suggest that NFκB signaling is activated in GD2+ cells and inhibition of this pathway by IKKα knockdown inhibits GD2 and GD3S expression in breast cancer cells.

NFκB inhibition by BMS-345541 suppresses tumorigenic and metastatic characteristics in BCSCs

We recently reported that the overexpression of the NFκB (p65) super-repressor inhibited GD3S expression in breast cancer cells [6], suggesting that NFκB signaling could be an important regulator in BCSC tumorigenic functions. To examine this further, we tested several small-molecule NFκB signaling inhibitors, including JSH-23, wedelolactone, and BMS-345541 to determine their effect on BCSC functions. We found that BMS-345541 was very effective. Treatment of MDA-MB-231 cells with this agent inhibited canonical pathway-associated proteins, including pNFκB (p65), as well as non-canonical pathway-associated proteins, including RelB, in a dose-dependent manner (Figure 2A).

To test whether BMS-345541 could also inhibit GD2+ cell growth, MDA-MB-231 and SUM159 cells were treated with BMS-345541 at various concentrations (i.e., 0.625, 1.25, 2.5, and 5 μM) or an equal volume of the vehicle PBS (control) for 24, 48, or 72 h. Treatment with BMS-345541 decreased the percentage of GD2+ MDA-MB-231 cells from 12.5% ± 3% to 1.5% ± 1%, and it inhibited the absolute number of GD2+ cell numbers by >90% in a dose- and a time-dependent manner (Figure 2B and 2C). We have reported that GD2 expression is tightly regulated by GD3S in BCSCs [5]. Therefore, we next tested whether BMS-345541 could inhibit GD3S expression at the transcription level. In MDA-MB-231 cells treated with BMS-345541, GD3S mRNA expression was dramatically inhibited, by >98% (Figure 2D), indicating that GD3S expression is highly dependent on active NFκB signaling.
Figure 1: Activation of NFκB signaling in GD2+ cells. A. MDA-MB-231 cells were stained with anti-GD2 conjugated with phycoerythrin (fluorochrome) or Sm152 (metal) and analyzed on an LSR II flow cytometer or by CyTOF, respectively. The data were analyzed on FlowJo software. B. MDA-MB-231 cells were incubated with anti-GD2 antibody conjugated with Sm152, anti-pNFκB(p65) conjugated with Sm149, anti-pPI3K(Y607) antibody conjugated with Gd158, and anti-pmTOR(S248) antibody conjugated with Dy164. All the samples were co-stained with and iridium (DNA-intercalator) conjugated with Rh103 for gating. The cells were analyzed on by CyTOF. The data were analyzed using the SPADE complex data analysis tool. A gradient from green (low) to red (high) indicates expression of each marker in different populations in the SPADE tree structure. C. qRT-PCR analysis of IKKα in control and IKKα knockdown MDA-MB-231 cells. D. Western blot analysis to determine IKKα and GD3S protein expression in control and IKKα knockdown MDA-MB-231 cells. E. Bar graph represents quantification of IKKα and GD3S protein expression in control and IKKα knockdown MDA-MB-231 cells. GAPDH served as loading control. F. Flow cytometry analysis was performed to measure GD2 expression in control and IKKα knockdown MDA-MB-231 cells. G. Bar graph represents the percentage of GD2+ cells in control and IKKα knockdown MDA-MB-231 cells.
Figure 2: BMS-345541 inhibits GD2 and GD3S expression by inhibiting NFκB signaling in breast cancer cells. A) MDA-MB-231 cells were treated with or without varying concentrations of BMS-345541 for 24 h. For the western blot, the cell lysates were run on a gel, and the transfer membranes were incubated with anti-pNFκB or anti-RelB antibodies. GAPDH served as a loading control. B) MDA-MB-231 cells were treated with BMS-345541 at concentrations of 1, 2.5, and 5 μM for 72 h. The cells were then stained with anti-GD2 antibody conjugated with allophycocyanin and analyzed on an LSR II flow cytometer. The cells were also stained with DAPI to exclude dead cells. C) The bar graph represents the absolute number of GD2+ cells from the experiment in Figure 2A. The assay was performed using TruCount absolute counting beads. D) GD3S mRNA expression analysis by quantitative RT-PCR. MDA-MB-231 cells were treated with BMS-345541 at concentrations of 0.1, 1, or 5 μM for 24 h. Relative GD3S mRNA expression levels were analyzed by TaqMan quantitative RT-PCR using the 7900HT fast real-time polymerase chain reaction system. 18S RNA served as the equal loading control.
Table 1: Proteins up- or down-regulated in GD2+ compared with GD2- cells

| Target Protein Name | Phospho Site (Human) | Full Target Protein Name | Z-ratio (SUM159-GD2+, SUM159-GD2-) |
|---------------------|----------------------|--------------------------|-----------------------------------|
| Caveolin 2          | Pan-specific         | Caveolin 2                | 3.12                              |
| Cyclin E            | T395                 | Cyclin E1                 | 1.89                              |
| Csk                 | Pan-specific         | C-terminus of Src tyrosine kinase | 1.89                             |
| p38a MAPK           | Pan-specific         | Mitogen-activated protein-serine kinase p38 alpha | 1.82                             |
| STAT2               | Pan-specific         | Signal transducer and activator of transcription 2 | 1.80                             |
| S6K                 | S411                 | p70 ribosomal protein-serine S6 kinase | 1.78                             |
| CDK1 (CDC2)         | Pan-specific         | Cyclin-dependent protein-serine kinase 1 | 1.76                             |
| PKR1                | T446                 | Double-stranded RNA-dependent protein-serine kinase | 1.73                             |
| RelB                | S573                 | Transcription factor RelB | 1.67                              |
| PKG1                | Pan-specific         | Protein-serine kinase G1 (cGMP-dependent protein kinase) | 1.67                             |
| p25                 | Pan-specific         | CDK5 regulatory subunit p25 | 1.51                              |
| Pyk2                | Pan-specific         | Protein-tyrosine kinase 2 | 1.40                              |
| IKKa                | T25                  | Inhibitor of NF-kappa-B protein-serine kinase alpha (CHUK) | 1.31                             |
| Cofilin 1           | Pan-specific         | Cofilin 1                 | 1.26                              |
| YSK1                | Pan-specific         | Serine/threonine-protein kinase 25 | 1.25                             |
| PKCh                | T655                 | Protein-serine kinase C eta | 1.24                             |
| Cbl                 | Y700                 | Signal transduction protein CBL | 1.23                             |
| MDM2                | S166                 | double minute 2           | 1.21                              |
| NFKB p65            | S536                 | NF-kappa-B p65 nuclear transcription factor | 1.18                             |
| IFHR23B             | Pan-specific         | UV excision repair protein RAD23 homolog B | 1.17                             |
| anti-actin          | Pan-specific         | Actin                     | 1.15                              |
| RSK1                | Pan-specific         | Ribosomal S6 protein-serine kinase 1 | 1.12                             |
| Smad2               | T200                 | Mothers against decapentaplegic homolog 2 | 1.05                             |
| Cdc34               | Pan-specific         | Cell division cycle 34 (ubiquitin-conjugating ligase) | 1.05                             |
| PKCe                | Pan-specific         | Protein-serine kinase C epsilon | 1.02                             |
| Hsp90a/b            | Pan-specific         | Heat shock 90 kDa protein alpha/beta | 1.01                             |
| Hsp90               | Pan-specific         | Heat shock 90 kDa protein 1 (chaperonin, CPN60) | -1.02                             |
| mMOB1               | Pan-specific         | Preimplantation protein 3 | -1.03                             |
| Histone H2B         | S15                  | Histone H2B               | -1.03                             |
| JAK2                | Y1007+Y1008          | Janus protein-tyrosine kinase 2 | -1.06                             |
| Histone H3          | S29                  | Histone H3.3              | -1.08                             |
| JAK3                | Pan-specific         | Janus protein-tyrosine kinase 3 | -1.09                             |
| c-IAP1              | Pan-specific         | Cellular inhibitor of apoptosis protein 1 (baculoviral IAP repeat-containing protein 3, apoptosis inhibitor 2 (API2)) | -1.10                             |
| Bcl-xS/L            | Pan-specific         | Bcl2-like protein 1       | -1.12                             |
| Bcl-xL              | Pan-specific         | Bcl2-like protein 1       | -1.13                             |
| KAP                  | Pan-specific         | Cyclin-dependent kinase associated phosphatase (CDK inhibitor 3, CIP2) | -1.15                             |
| p107                | Pan-specific         | Retinoblastoma (RB) protein-related p107 (PRB1) | -1.16                             |
| Catenin b1          | Pan-specific         | Catenin (cadherin-associated protein) beta 1 | -1.18                             |
| EGFR                | Y1172                | Epidermal growth factor receptor-tyrosine kinase | -1.19                             |
| Hsp90a/b            | Pan-specific         | Heat shock 90 kDa protein alpha/beta | -1.21                             |
| GFAP                | S8                   | Glial fibrillary acidic protein | -1.22                             |
| GRK2 (BARK1)        | Pan-specific         | G protein-coupled receptor-serine kinase 2 | -1.25                             |
| Hsp27               | S15                  | Heat shock 27 kDa protein beta 1 (HspB1) | -1.27                             |
| Cyclin A            | Pan-specific         | Cyclin A1                 | -1.29                             |
| Erk1 + Erk2         | T202                 | Extracellular regulated protein-serine kinase 1 (p44 MAP kinase)+ Extracellular regulated protein-serine kinase 2 (p42 MAP kinase) | -1.30                             |
| EGFR   | Pan-specific | Epidermal growth factor receptor-tyrosine kinase | -1.31 |
|--------|--------------|--------------------------------------------------|-------|
| IkBα   | Pan-specific | Inhibitor of NF-kappa-B beta (thyroid receptor interacting protein 9) | -1.47 |
| CDK9   | Pan-specific | Cyclin-dependent protein-serine kinase 9          | -1.49 |
| Fos    | Pan-specific | Fos-c FBJ murine osteosarcoma oncprotein-related transcription factor | -1.81 |
| PP2A/Ca| Pan-specific | Protein-serine phosphatase 2B - catalytic subunit - alpha isoform | -1.83 |
| IkBα   | Pan-specific | Inhibitor of NF-kappa-B alpha (MAD3)               | -2.27 |

Protein lysates from SUM159 cells were analyzed on antibody microarrays (Kinexus). Differentially expressed or activated proteins are listed. Z score transformation provides a way of standardizing data across a wide range of experiments and allows the comparison of independent datasets. Data normalized by Z score transformation can be used directly in the calculation of statistically significant changes in gene expression between different samples. Z-ratio given below are obtained using methods described before [15].

To investigate whether BMS-345541 could inhibit the behavior of BCSCs, we treated MDA-MB-231 and SUM159 cells with various concentrations of BMS-345541 and tested their ability to endure anchorage-independent growth in soft agar and as mammospheres, and also their ability to undergo migration and invasion in vitro. BMS-345541 treatment inhibited anchorage-independent mammosphere formation in both MDA-MB-231 (Figure 3A) and SUM159 cells (Figure 3B) by 4- to 5-fold compared with the vehicle control. Soft agar colony assay revealed that BMS-345541 inhibited growth by > 98% in MDA-MB-231 cells and by > 60% in SUM159 cells, suggesting that NFκB-mediated signaling is required for BCSC tumorigenic qualities (Figure 2C and 2D). Interestingly, the migration assay revealed that BMS-345541 treatment inhibited this activity by SUM159 by approximately 10-fold (Figure 2E). The matrigel assay using trans-well chambers revealed that BMS-345541 treatment triggered a concentration-dependent inhibition in invasion of SUM159 cells by > 95% in (Figure 2F). These results suggest that BMS-345541 could inhibit NFκB, which was seemingly coupled to the tumorigenic characteristics of BCSCs.

**BMS-345541 inhibits breast tumor growth and metastases in vivo**

To investigate the effect of BMS-345541 on in vivo tumor growth, 1 × 10⁶ MDA-MB-231 cells expressing GFP and firefly luciferase were implanted in mammary fat pads of NSG mice (n = 14). Upon palpable tumor formation (in roughly 2 wk), the mice were divided into two groups (n = 7 per group) and treated with PBS or 25 mg/kg BMS-345541 for 3 d per week for 4 wk via intra-peritoneal (IP) injections. Tumor growth was measured on a weekly basis by bioluminescence imaging (Figure 4A). We found that BMS-345541 treatment reduced tumor growth 2- to 3-fold compared to the control (Figure 4B). In addition, BMS-345541 treatment increased median survival of the mice by > 2 wk compared with the control (Figure 4C, 78 d for the BMS-345541-treated group vs. 58 d for the control-treated group; P < 0.002), suggesting that the inhibition of NFκB by BMS-345541 could inhibit breast tumor growth in vivo presumably by blocking BCSC function.

To investigate whether BMS-345541 inhibits breast cancer metastases, we used an experimental metastasis model and intravenously implanted MDA-MB-231 cells expressing GFP and firefly luciferase in NSG mice (n = 10). One d after implantation, bioluminescence imaging was performed to ensure that all the mice had similar engraftment. Three d after implantation, the mice were divided into two groups and started on treatment with PBS or BMS-345541 (25 mg/kg) for 3 d per wk for 4 wk via intravenous injections. Tumor metastases were measured weekly by bioluminescence imaging. We found that BMS-345541 treated mice showed a reduction of reduced total bio-luminescence flux of 2- to 3-fold compared to the controls (Figure 5A). Immunohistochemical analysis by hematoxylin-eosin staining of lung tissues revealed that the BMS-345541-treated group had 3- to 4-fold fewer metastases than the PBS-treated group (Figure 5B). In addition, the size of the metastases was also significantly smaller for the mice treated with BMS-345541 (Figure 5C), indicating that BMS-345541 inhibits GD2+ BCSC function and thereby inhibits breast cancer metastases.

**DISCUSSION**

We found that inhibition of NFκB signaling using the IKK blocker BMS-345541 suppressed GD2+ cell number apparently by inhibiting GD3S expression. In addition, BMS-345541 inhibited the tumorigenic function of BCSCs in vitro, and also inhibited in vivo tumor growth and metastases in immunodeficient mice implanted with BCSCs, suggesting a critical role of NFκB signaling in BCSC function.

We have previously reported that the ganglioside GD2 identifies BCSCs and that GD3S regulates GD2 expression in these cells [5]. In addition, treatment with the anti-inflammatory and anti-cancer drug triptolide dramatically inhibited GD2+ cells by inhibiting GD3S in MDA-MB-231 and SUM159 cells [5, 6], but the mechanism of action was not known. Triptolide has been reported to inhibit NFκB signaling in T-lymphocytes [17]. Previous studies also report the regulation of breast cancer
Figure 3: BMS-345541 inhibits function of BCSCs. A. The bar graphs represent the number of mammospheres formed per 5000 MDA-MB-231 (A) or SUM159 (B) cells seeded in low-adherent conditions with varying concentrations of BMS-345541 for 2 wk. C. and D. MDA-MB-231 (C) or SUM159 (D) cells were plated into soft agar with varying concentrations of BMS-345541. After 3 weeks of incubation, colonies were fixed with MTT and then counted using an automated colony counter. E. SUM159 cells were plated into transwell migration plates with varying concentrations of BMS-345541. After 6 h, the membrane was fixed and stained, and then cells were counted. F. SUM159 cells were plated into transwell invasion plates with matrigel; the media contained varying concentrations of BMS-345541. After 24 h, the membrane and Matrigel were removed, and the cells were counted.
stem cells by NFκB signaling, but did not measure NFκB activation exclusively in BCSCs [14, 18]. In this report, we show that NFκB signaling is activated in GD2+, but not in GD2- breast cancer cells. In addition, we identify BMS345541 as potential tool for modulating GD3S and GD2 by interrupting NFκB signaling.

Activation of NFκB signaling in breast cancer has been reported by several investigators [11-13]. Singh et al. first showed NFκB activation in estrogen receptor-negative and Her2+ breast tumors and suggested NFκB as a therapeutic target [12]. Cogswell et al. reported selective activation of the IκB super-repressor inhibited GD3S expression in MDA-MB-231 and human mammary epithelial cells expressing Ras oncogene (HMLER). Kang et al. first identified the GD3S promoter sequence (-1146 to -646) in Jurkat T-cells and reported

Figure 4: BMS-345541 reduces the rate of tumor growth and increases survival in tumor-bearing mice. A. GFP/luciferase-expressing MDA-MB-231 cells were implanted into the mammary fat pads of mice (n = 14), who were then split into two treatment groups (Seven mice per group); one group was treated with BMS-345541 (25 mg/kg for three treatments per wk for 4 wk), while the other group was treated with control. The images show the luciferase activity in the mice over time. B. The bar graph represents the luminescence levels in the two groups of tumor-bearing mice. The y-axis represents the number of photons emitted. C. Survival analysis: Ten mice received MDA-MB-231 cells (1 × 10⁶ cells per mouse) in the mammary fat pads. One group was treated with BMS-345541, while the other group was treated with PBS as a control (three injections per week for 1 week). The survival curves were generated using Prism software (GraphPad Software, San Diego, CA).
Figure 5: BMS-345541 inhibits cancer metastasis in *in vivo* settings. **A.** GFP/luciferase-expressing MDA-MB-231 cells were injected into the tail veins of NSG mice (*n* = 10) in an experimental metastatic model. The mice were then split into two treatment groups; one group (5 mice per group) was treated with BMS-345541, while the other group was treated with PBS. The bar graph represents the luciferase activity of the groups. **B.** H and E staining of lung tissues derived from mice in experiment described in Figure 5A. The sections are derived from mice on d 34 after tumor implantation. **C.** and **D.** To quantitate the amount of metastasis in each group, lungs derived from treated and untreated groups on d 34 were stained with hematoxylin and eosin, and the sections were scanned using EVOS-FL auto microscope and the metastasis was quantitated using inForm software (PerkinElmer). **E.** The image illustrates the mechanism of action for BMS-345541, an IKK inhibitor. Through inhibition of IKK activity, IκB fails to get phosphorylated, leading to the inhibition of NFκB translocation across the nuclear membrane and inhibition of GD3S and GD2 expression.
several transcription factors, including cETS1, CREB, AP-1, and NFκB binding sites, in the GD3S promoter sequence [19]. Deletion of NFκB binding sites inhibited Fas-induced GD3S expression, suggesting that GD3S and GD2 expression may depend on NFκB signaling. Reports from Bobowski et al. that estradiol inhibits GD3S expression in breast cancer cells by preventing NFκB to the GD3S promoter [20] further strengthens our current finding that NFκB regulates GD3S and GD2 expression.

Recent reports also suggest that the NFκB pathway is highly activated in cancer-initiating cells, specifically in BCSCs [18]. Yamamoto et al. reported that NFκB non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype [14]. The authors found that NFκB regulates JAG-1 expression and that the NIK-NFκB-JAG1-NOTCH axis regulates the BCSC population. Moreover, Park et al. reported that NFκB signaling promotes osteolytic bone metastasis by inducing osteoclastogenesis via granulocyte macrophage colony-stimulating factor [21]. In this report, the authors found that granulocyte macrophage colony-stimulating factor is a key target of NFκB and mediates osteolytic bone metastasis of breast cancer by stimulating osteoclast development. Similarly, our metastases data indicate that BMS-345541 treatment inhibits breast cancer metastases in mice by inhibiting GD2+ BCSCs, suggesting a critical role of NFκB signaling in breast cancer metastasis.

Kendellen et al. reported that both canonical and non-canonical NFκB pathways promote BCSCs. Knockdown of IKKα or IKKβ inhibited epithelial-mesenchymal transition marker expression [22]. We tried several inhibitors, including JSH-23, wedelolactone, and BMS-345541, to inhibit NFκB activity and its downstream targets; only BMS-345541 successfully inhibited GD3S and GD2 expression in a concentration-dependent manner (Figure 2). BMS-345541 targets both IKKα (half maximal inhibitory concentration: 4.2 μM) and IKKβ (half maximal inhibitory concentration: 0.4 μM) [23], which could be why BMS-345541 was more effective in inhibiting GD3S expression than the other NFκB inhibitors. A low effective dosage, high specificity for GD2+ BCSCs, inhibition of BCSC growth in vivo and in vitro make BMS-345541 a potential therapeutic tool for basal-like or triple-negative breast cancer subtypes and suitable for clinical trials.

In conclusion, our data indicate that NFκB-mediated signaling is activated in GD2+ BCSCs and regulates GD3S expression. BMS-345541 appears to inhibit canonical and non-canonical NFκB signaling by blocking IKKα and β in GD2+ cells inhibiting their ability to form tumors. In combination with conventional chemotherapeutic agents, BMS-345541 could be a potential therapeutic tool in the treatment of metastatic breast cancer.

MATERIALS AND METHODS

Cell culture

Human breast cancer cell lines MDA-MB-231 and SUM159 were cultured according to American Type Culture Collection recommendations.

Flow cytometry analysis and fluorescence-activated cell sorting (FACS)

Single-color staining of MDA-MB-231 and SUM159 cells was performed as described previously [24]. Briefly, ~1 × 10⁶ cells were washed twice with phosphate-buffered saline (PBS) containing 1% fetal bovine serum (FACS buffer), incubated with anti-GD2 antibody conjugated with allophycocyanin (APC, BioLegend, San Diego, CA) for 30 minutes on ice, and washed in FACS buffer containing 4',6-diamidino-2-phenylindole (DAPI) (0.5 mg/ml). After being washed, the cells were analyzed with an LSR II flow cytometer (BD; Franklin Lakes, NJ), and the cytometry data were analyzed using FlowJo software. At least 1 × 10⁵ events were measured per sample. FACS was performed to isolate GD2+ and GD2- cells from MDA-MB-231 and SUM159 cells. Cells were stained with anti-GD2 antibody as described above, and sorting was performed on a FACSARia II cell sorter (BD Biosciences, Franklin Lakes, NJ). The absolute number of cells was found using TruCount counting beads (BD Biosciences) per the manufacturer’s instructions.

Proteomic analysis

To investigate signaling pathways activated in BCSCs, GD2+ and GD2- MDA-MB-231 and SUM159 cells underwent FACS and were analyzed on an antibody microarray (Kinexus, Vancouver, Canada). Briefly, the cell lysates from GD2+ and GD2- cells were labeled with fluorescent probes and applied to glass slides coated with 850 validated antibodies against various total proteins and phosphoproteins per the manufacturer’s instructions. After washes, the staining was developed and analyzed on a phosphoimager. The Z-ratio was calculated as described previously [15], and proteins with differential expression or phosphorylation between GD2+ and GD2- cells were identified. To understand the functional significance of and signaling pathways associated with GD2 and GD3S expression, we analyzed differentially expressed or activated proteins using Ingenuity Pathway Analysis software (Ingenuity Systems, Redwood City, CA).
Generation of stable IKKα knockdown breast cancer cells

We used pLKO lentiviral vectors expressing shRNA against IKKα (Catalog # RHS3979-201732780; GE Dharmacon, Lafayette, CO) to knockdown IKKα in MDA-MB-231 cells. Lentiviral particle expressing IKKα shRNA were generated using packaging vectors as described previously [5]. The viral supernatant was then incubated with MDA-MB-231 cells for 48 h and the transduced clones were selected by incubating the cells in puromycin (ThermoFisher Scientific), containing cell culture medium at 2 µg/ml concentration.

Western blotting

Western blotting was performed as described before [25]. Briefly, 1 million cells were plated into 100-mm-wide tissue culture dishes and incubated at 37°C and 5% CO₂ for 24 hours to allow for adjustment and adherence. The cells were treated with PBS or BMS-345541 at various concentrations, including 0.0625, 1.25, 2.5, and 5 µM, for 24 hours. Cells were subjected to lysis at a density of 3 × 10⁵/50 µl in protein lysis buffer (G-Biosciences, St. Louis, MO), mixed with 2× laemmli buffer (Bio-Rad, Hercules, CA) at 1:1 ratio, and supplemented with a protease inhibitor cocktail (Roche Diagnostics, Risch-Rotkreuz, Switzerland). Cell lysates were loaded onto 10% polyacrylamide gel (Bio-Rad) for electrophoresis, and then the proteins were transferred to Immobilon-FL membranes (EMD Millipore, Billerica, MA). The membranes were incubated with rabbit anti-pNFκB or rabbit anti-RelB (both from Cell Signaling Technology, Danvers, MA) at a 1:500 or 1:1000 dilution and with mouse anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibodies at a 1:10,000 dilution overnight at 4°C. The membranes were then washed and incubated with donkey anti-mouse immunoglobulin G antibody conjugated with Alexa Fluor 700 and donkey anti-goat antibody conjugated with Alexa Fluor 800 (both from Thermo Fisher Scientific, Waltham, MA). GAPDH served as a loading control.

Real-time reverse transcription polymerase chain reaction (RT-PCR)

A total of 5 × 10⁷ MDA-MB-231 or SUM159 breast cancer cells were incubated with BMS-345541 at concentrations of 0.625, 1.25, 2.5, and 5 µM or the control for 24 h at 37°C in six-well cell culture dishes. Real-time RT-PCR was performed using TaqMan gene expression assays from Applied Biosystems (Carlsbad, CA) as described previously [26]. The assay for GD3S was Hs00268157, and the assay for GAPDH was Hs02758991.

Mass cytometry

To compare activation of cell signaling proteins between GD2⁺ and GD2⁻ MDA-MB-231 cells, Time-of-flight mass cytometry (CyTOF), a novel technology combining atomic mass spectrometry and flow cytometry, was performed as described before [27]. Briefly, the cells were fixed in 1.6% formaldehyde to stop signal transduction and place the cells in stasis. We then incubated the cells with extracellular anti-GD2 antibody (clone 14.G2a; BD Biosciences) conjugated with samarium (isotopic mass: 152). Once extracellular antibody binding was complete, the cells were fixed and permeabilized with 50% methanol and then were incubated with an intracellular antibody cocktail (Roche Diagnostics, Risch-Rotkreuz, Switzerland). The cells were then washed and stained with iridium dye (DNA intercalator-Rh103;Fluidigm) overnight to prepare for CyTOF. PBS with 0.5% bovine serum albumin was used as a wash and incubation buffer throughout, as it acts as a carrier protein, improving antibody binding and aiding with washing. The cells were analyzed on CyTOF mass cytometry (Fluidigm, South San Francisco, CA). The data were saved in Flow Cytometry Standard 3.0 format and analyzed by spanning-tree progression analysis of density-normalized events (SPADE) software, a novel tool for analyzing complex data sets involving multiple parameters [28].

Mammosphere assay

To investigate the effect of BMS-345541 on the mammosphere formation potential of MDA-MB-231 and SUM159 cells, 1 × 10² or 1 × 10³ cells were plated in ultra-low attachment 24-well dishes containing mammosphere growth medium (Stemcell Technologies, Vancouver, BC, Canada). The cells were treated with or without BMS-345541 at concentrations of 0.625, 1.25, 2.5, and 5 µM. After 10 to 12 d of culture at 37°C in humidified air containing 5% CO₂, the resulting mammospheres were counted using a microscope.
Migration assays

Migration assays were performed using 24-well trans-well chambers as described previously [5]. Membrane inserts with 8-µm pores (Corning, Kennebunk, ME) were used to test the effect of BMS-345541 on cellular migration. The bottom chamber was filled with complete cell culture medium with 10% FCS. Added to the upper chamber were 3 × 10³ MDA-MB-231 or SUM159 cells that were suspended in 200 µl of Dulbecco’s Modified Eagle Medium containing 1% FCS and BMS-345541 at concentrations of 0.625, 1.25, 2.5, and 5 µM and the control. The chambers were incubated at 37°C and 5% CO₂ for 6 h. The cells that migrated to the other side of the membrane were stained with DAPI (Life Technologies, Carlsbad, CA) and counted under the EVOS-FL automated microscope (Thermo Fisher Scientific).

In vitro matrigel invasion assay

In vitro migration and invasion assays were performed using 24-well Biocoat Matrigel Invasion Chambers (Corning) containing BD Falcon Cell Culture Inserts with a polyethylene terephthalate membrane (8-µm-diameter pore size) treated with Matrigel Matrix (BD Biosciences) as described previously [5]. Briefly, cell suspensions of MDA-MB-231 and SUM159 cells were placed in the Matrigel-coated upper chamber. After incubation at 37°C for 24 h in a 5% CO₂ incubator, the residual cells on the upper surface of the filter were completely removed with cotton swabs. The membranes were then stained, and the cells were counted.

In vitro tumorigenesis assay

Two and half milliliters of liquefied solution of 1% low-melting agarose (Thermo Fisher Scientific, Fair Lawn, NJ) in DMEM medium with 10% FCS with appropriate drug concentrations (BMS-345541 at 0, 0.625, 1.25, 2.5, and 5 µM) was added to each well in a six-well plate. After the plates were cooled at 4°C for 1 hour, an additional 2.5 ml of 0.5% agarose, complete media solution, the same drug concentrations as above, and 5000 MDA-MB-231 or SUM159 cells were added to each well. The plates were then cooled at 4°C for 30 min and then incubated at 37°C and 5% CO₂ for 3 wk (100 µl of media were added weekly to avoid drying of the soft agar gels). The resulting colonies were fixed and stained using 200 µl/well of 1 mg/ml of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Alfa Aesar, Heysham, United Kingdom). The colonies were then counted using an automated colony counter (Oxford Optronix, Abingdon, United Kingdom).

Statistical analyses

Unless otherwise indicated, data are mean ± standard error of the mean. The statistical significance of tumor growth was determined by a two-way analysis of variance for repeated measures. All other group differences were evaluated by two-tailed unpaired Student t-tests. Survival data were analyzed using Kaplan-Meier log-rank tests. A P < 0.05 was considered statistically significant.
Authors’ contributions

Venkata Lokesh Battula conceptualized and designed and performed experiments and wrote the manuscript, Khoa Nguyen performed experiments and wrote manuscript, Jeffrey Sun, Mary Kathryn Pitner, and Bin Yuan performed experiments, Chandra Bartholomeusz performed data analysis, Numsen Hail Jr. edited the manuscript, and Michael Andreeff conceptualized the study and edited the manuscript.

ACKNOWLEDGMENTS

The University of Texas MD Anderson Cancer Center is supported in part by the National Institutes of Health through the Cancer Center Support Grant P30CA016672, and by the Breast Cancer Research Foundation (BCRF, both to MA). The authors would also like to thank Vivian Ruvolo for technical guidance in viral transductions. Time-of-flight mass cytometry was performed at the Flow Cytometry and Cellular Imaging core facility at MD Anderson Cancer Center.

CONFLICTS OF INTEREST

The authors declare no financial interests in the findings described in the manuscript.

REFERENCES

1. Korkaya H, Wicha MS. Breast cancer stem cells: we’ve got them surrounded. Clinical Cancer Research. 2013; 19:511-513.
2. Schatton T, Frank NY, Frank MH. Identification and targeting of cancer stem cells. Bioessays. 2009; 31:1038-1049.
3. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011; 331:1559-1564.
4. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, Liu H, Wu MF, Gee AP, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011; 118:6050-6056.
5. Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO, Guerra R, Sahin AA, Marini FC, Hortobagyi G, Mani SA, Andreeff M. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. Journal of Clinical Investigation. 2012; 122:2066-2078.
6. Sarkar TR, Battula VL, Werden SJ, Vijay GV, Ramirez-Pena EQ, Taube JH, Chang JT, Miura N, Porter W, Sphyris N, Andreeff M, Mani SA. GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene. 2015; 34:2958-2967.
7. Senflleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, Karin M. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science. 2001; 293:1495-1499.
8. Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, Makris C, Li ZW, Karin M, Ware CF, Green DR. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity. 2002; 17:525-535.
9. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends in Immunology. 2004; 25:280-288.
10. Novack DV, Yin L, Hagen-Stapleton A, Schreiber RD, Goeddel DV, Ross FP, Teitelbaum SL. The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. Journal of Experimental Medicine. 2003; 198:771-781.
11. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, Iglehart JD. NF-kappaB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proceedings of the National Academy of Sciences U S A. 2004; 101:10137-10142.
12. Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart JD, Biswas DK. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. Molecular Cancer Therapeutics. 2007; 6:1973-1982.
13. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS Jr. Selective activation of NF-kappaB2 subunits in human breast cancer: potential roles for NF-kappaB2/p52 and for Bcl-3. Oncogene. 2000; 19:1123-1131.
14. Yamamoto M, Taguchi Y, Ito-Kureha T, Semba K, Yamaguchi N, Inoue J. NF-kappaB non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype. Nature Communications. 2013; 4:2299.
15. Cheadle C, Vawter MP, Freed WJ, Becker KG. Analysis of microarray data using Z score transformation. Journal of Molecular Diagnostics. 2003; 5:73-81.
16. Qiu P, Simonds EF, Bendall SC, Gibbs KD Jr, Bruggner RV, Linderman MD, Sachs K, Nolan GP and Plevritis SK. Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nature Biotechnology. 2011; 29:886-891.
17. Liu H, Liu ZH, Chen ZH, Yang JW, Li LS. Triptolide: a potent inhibitor of NF-kappa B in T-lymphocytes. Acta Pharmacologica Sinica. 2000; 21:782-786.
18. Shostak K and Chariot A. NF-kappaB, stem cells and breast cancer: the links get stronger. Breast Cancer Research. 2011; 13:214.
19. Kang NY, Kang SK, Lee YC, Choi HJ, Lee YS, Cho SY, Kim YS, Ko JH, Kim CH. Transcriptional regulation of the human GD3 synthase gene expression in Fas-induced Jurkat T cells: a critical role of transcription factor NF-kappaB in
regulated expression. Glycobiology. 2006; 16:375-389.

20. Bobowski M, Vincent A, Steenackers A, Colomb F, Van Seuningen I, Julien S, Delannoy P. Estradiol represses the G(D3) synthase gene ST8SIA1 expression in human breast cancer cells by preventing NFkappaB binding to ST8SIA1 promoter. PLoS One. 2013; 8:e62559.

21. Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T, Gu K, Shah V, Pei L, Zarbo RJ, McCauley L, Shi S, Chen S, et al. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nature Medicine. 2007; 13:62-69.

22. Kendellen MF, Bradford JW, Lawrence CL, Clark KS, Baldwin AS. Canonical and non-canonical NF-kappaB signaling promotes breast cancer tumor-initiating cells. Oncogene. 2014; 33:1297-1305.

23. Burke JR, Pattoli MA, Gregor KR, Brassil PJ, MacMaster JF, McIntyre KW, Yang X, Iotzova VS, Clarke W, Strnad J, Qiu Y, Zusi FC. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. Journal of Biological Chemistry. 2003; 278:1450-1456.

24. Battula VL, Treml S, Bareiss PM, Gieseke F, Roelofs H, de Zwart P, Muller I, Schewe B, Skutella T, Fibbe WE, Kanz L, Buhring HJ. Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haematologica. 2009; 94:173-184.

25. Battula VL, Chen Y, Cabreira Mda G, Ruvolo V, Wang Z, Ma W, Konoplev S, Shpall E, Lyons K, Strunk D, Bueso-Ramos C, Davis RE, Konopleva M, et al. Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment. Blood. 2013; 122:357-366.

26. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006; 10:375-388.

27. Han L, Qiu P, Zeng Z, Jorgensen JL, Mak DH, Burks JK, Schober W, McQueen TJ, Cortes J, Tanner SD, Roboz GJ, Kantarjian HM, Kornblau SM, et al. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry A. 2015; 87:346-356.

28. Bendall SC, Simonds EF, Qiu P, Amir el AD, Krutzik PO, Finck R, Bruggner RV, Melamed R, Trejo A, Ornatsky OI, Balderas RS, Plevritis SK, Sachs K, et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science. 2011; 332:687-696.